Mibefradil: A New Selective T-Channel Calcium Antagonist for Hypertension and Angina Pectoris

No abstract is available for this paper.

• Publication year

  1997

• Venue

  Journal of Cardiovascular Pharmacology and Therapeutics

• Publication date

  1997-12-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1177/107424849700200410PMID 10684473
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Safety of mibefradil, a new once-a-day, selective T-type calcium channel antagonist.

  1997influential reference
• The addition of mibefradil to chronic hydrochlorothiazide therapy in hypertensive patients is associated with a significant antihypertensive effect

  1997cited by this paper
• Long-term antianginal and antiischemic effects of mibefradil, the novel T-type calcium channel blocker: a multicenter, double-blind, placebo-controlled, randomized comparison with sustained-release diltiazem.

  1997cited by this paper
• Mibefradil, a novel calcium antagonist, in elderly patients with hypertension: favorable hemodynamics and pharmacokinetics.

  1997cited by this paper
• The design of the Mortality Assessment in Congestive Heart Failure Trial (MACH-1, mibefradil).

  1997cited by this paper
• Pharmacologic and pharmacokinetic profile of mibefradil, a T- and L-type calcium channel antagonist.

  1997cited by this paper
• Pharmacology of the calcium antagonist mibefradil

  1997cited by this paper
• Antianginal and anti-ischemic effects of mibefradil in the treatment of patients with chronic stable angina pectoris.

  1997cited by this paper
• Dose-response characteristics of mibefradil, a novel calcium antagonist, in the treatment of essential hypertension.

  1997cited by this paper
• Efficacy of mibefradil compared with amlodipine in suppressing exercise-induced and daily silent ischemia: results of a multicenter, placebo-controlled trial.

  1997cited by this paper
• Antihypertensive effects of mibefradil: A double‐blind comparison with diltiazem CD

  1997cited by this paper
• The design of the Mortality Assessment in Congestive Heart Failure Trial (MACH-1, mibefradil).

  1997cited by this paper
• A randomised, double-blind trial comparing mibefradil and amlodipine: two long-acting calcium antagonists with similar efficacy but different tolerability profiles

  1997cited by this paper
• Mibefradil in the treatment of systemic hypertension: comparative studies with other calcium antagonists.

  1997cited by this paper
• Additional antianginal and anti-ischemic efficacy of mibefradil in patients pretreated with a beta blocker for chronic stable angina pectoris.

  1997cited by this paper
• The antihypertensive efficacy of the novel calcium antagonist mibefradil in comparison with nifedipine GITS in moderate to severe hypertensives with ambulatory hypertension.

  1997cited by this paper
• The IVS6 segment of the L‐type calcium channel is critical for the action of dihydropyridines and phenylalkylamines.

  1996cited by this paper
• Antihypertensive properties of the novel calcium antagonist mibefradil (Ro 40-5967): a new generation of calcium antagonists? Mibefradil International Study Group.

  1996cited by this paper
• Effects of a new calcium antagonist, mibefradil (Ro 40-5967), on silent ischemia in patients with stable chronic angina pectoris: a multicenter placebo-controlled study. The Mibefradil International Study Group.

  1996cited by this paper
• The binding interactions of Ro 40-5967 at the L-type Ca2+ channel in cardiac tissue.

  1995cited by this paper
• Basal endothelial nitric oxide production and insulin sensitivity are positively related in man

  1995cited by this paper
• Interaction of Ro 40-5967 and verapamil with the stably expressed alpha 1-subunit of the cardiac L-type calcium channel.

  1995cited by this paper
• Single calcium channel behavior in native skeletal muscle

  1995cited by this paper
• Effects of the new calcium antagonist mibefradil (Ro 40-5967) on exercise duration in patients with chronic stable angina pectoris: a multicenter, placebo-controlled study. Ro 40-5967 International Study Group.

  1995cited by this paper
• ET‐1 Stimulates Ca2+ Currents in Cardiac Cells

  1995cited by this paper
• Haemodynamics, cardiac conduction and pharmacokinetics of mibefradil (Ro 40–5967), a novel calcium antagonist

  1995cited by this paper
• Mibefradil prevents neointima formation after vascular injury in rats. Possible role of the blockade of the T-type voltage-operated calcium channel.

  1995cited by this paper
• Chronic treatment with the CA2+ channel inhibitor RO 40-5967 potentiates endothelium-dependent relaxations in the aorta of the hypertensive salt sensitive Dahl rat.

  1994cited by this paper
• Selective inhibition of T-type Ca2+ channels by Ro 40-5967.

  1994influential reference
• Endothelin ETA receptor antagonist blocks cardiac hypertrophy provoked by hemodynamic overload.

  1994cited by this paper
• Type III omega-agatoxins: a family of probes for similar binding sites on L- and N-type calcium channels.

  1994cited by this paper
• The Ca(++)-channel blocker Ro 40-5967 blocks differently T-type and L-type Ca++ channels.

  1994cited by this paper
• Three types of Ca2+ channel trigger secretion with different efficacies in chromaffin cells

  1994cited by this paper
• Ro40-5967, a New Calcium-antagonist Profile - Bradycardia Without Myocardial Depression

  1994cited by this paper
• Expression of voltage-gated calcium channels correlates with PDGF-stimulated calcium influx and depends upon cell density in C3H 10T1/2 mouse fibroblasts.

  1993cited by this paper
• Cardiovascular Profile of Ro 40–5967, a New Nondihydropyridine Calcium Antagonist, Delineated in Isolated, Blood‐Perfused Dog Hearts

  1993cited by this paper
• Ca2+ channel actions of the non-dihydropyridine Ca2+ channel antagonist Ro 40-5967 in vascular muscle cells cultured from dog coronary and saphenous arteries

  1993cited by this paper
• New synthetic ligands for L-type voltage-gated calcium channels.

  1993cited by this paper
• Ca2+ influx via T-type channels modulates PDGF-induced replication of mouse fibroblasts.

  1993cited by this paper
• Potential‐dependent inward currents in single isolated smooth muscle cells of the rat ileum.

  1992cited by this paper
• Effect on prognosis of abolition of exercise-induced painless myocardial ischemia by medical therapy.

  1992cited by this paper
• Endothelin-1 enhances calcium entry through T-type calcium channels in cultured neonatal rat ventricular myocytes.

  1992cited by this paper
• Hemodynamic and humoral effects of the novel calcium antagonist Ro 40‐5967 in patients with hypertension

  1992cited by this paper
• Sites, mechanisms of action, and differentiation of calcium channel antagonists.

  1991cited by this paper
• Pulse rate, coronary heart disease, and death: the NHANES I Epidemiologic Follow-up Study.

  1991cited by this paper
• Ro 40–5967, in Contrast to Diltiazem, Does Not Reduce Left Ventricular Contractility in Rats with Chronic Myocardial Infarction

  1991cited by this paper
• Characteristics of calcium-current in isolated human ventricular myocytes from patients with terminal heart failure.

  1991cited by this paper
• Ro 40–5967: A New Nondihydropyridine Calcium Antagonist

  1991cited by this paper
• Pathological Hypertrophy and Cardiac Interstitium: Fibrosis and Renin‐Angiotensin‐Aldosterone System

  1991cited by this paper
• Endothelin-1 induces hypertrophy with enhanced expression of muscle-specific genes in cultured neonatal rat cardiomyocytes.

  1991cited by this paper
• Effect of endothelin-1 on cytosolic calcium ions in cultured human endothelial cells.

  1990cited by this paper
• Contribution of two types of calcium channels to membrane conductance of single myocytes from guinea‐pig coronary artery.

  1990cited by this paper
• Calcium channels in vertebrate cells.

  1990cited by this paper
• Silent ischemia during daily life is an independent predictor of mortality in stable angina.

  1990cited by this paper
• Multiple Types of Ca2+ Currents in Single Canine Purkinje Cells

  1989cited by this paper
• In vitro pharmacologic profile of Ro 40-5967, a novel Ca2+ channel blocker with potent vasodilator but weak inotropic action.

  1989cited by this paper
• Calcium channel blockers in acute myocardial infarction and unstable angina: an overview.

  1989cited by this paper
• Characteristics of L- and T-type Ca2+ currents in canine cardiac Purkinje cells.

  1989cited by this paper
• Classes of calcium channels in vertebrate cells.

  1989cited by this paper
• Low‐voltage‐activated calcium current in rat aorta smooth muscle cells in primary culture.

  1989cited by this paper
• Contribution of two types of calcium currents to the pacemaker potentials of rabbit sino-atrial node cells

  1989cited by this paper
• Effects of Ro 40-5967, a Novel Calcium Antagonist, on Myocardial Function During Ischemia Induced by Lowering Coronary Perfusion Pressure in Dogs: Comparison with Verapamil

  1989cited by this paper
• The epidemiology of resting heart rate in a national sample of men and women: associations with hypertension, coronary heart disease, blood pressure, and other cardiovascular risk factors.

  1988cited by this paper
• Ca channels in adrenal glomerulosa cells: K+ and angiotensin II increase T-type Ca channel current.

  1988cited by this paper
• Contribution of two types of calcium currents to the pacemaker potentials of rabbit sino‐atrial node cells.

  1988cited by this paper
• Regulation of one type of Ca2+ current in smooth muscle cells by diacylglycerol and acetylcholine

  1988cited by this paper
• Calcium currents in embryonic and neonatal mammalian skeletal muscle

  1988cited by this paper
• A novel potent vasoconstrictor peptide produced by vascular endothelial cells

  1988cited by this paper
• Inactivation, reactivation and pacing dependence of calcium current in frog cardiocytes: correlation with current density.

  1988cited by this paper
• Kinetics and selectivity of a low‐voltage‐activated calcium current in chick and rat sensory neurones.

  1987cited by this paper
• Rate of increase in the plasma concentration of nifedipine as a major determinant of its hemodynamic effects in humans

  1987cited by this paper
• Calcium channel antagonists and renin release.

  1987cited by this paper
• Acute and chronic sympathetic reflex activation and antihypertensive response to nifedipine.

  1986cited by this paper
• Two distinct populations of calcium channels in a clonal line of pituitary cells.

  1985cited by this paper
• Relationship between the stereoselective negative inotropic effects of verapamil enantiomers and their binding to putative calcium channels in human heart

  1985cited by this paper
• Two types of calcium channels in the somatic membrane of new‐born rat dorsal root ganglion neurones.

  1985cited by this paper
• Two kinds of calcium channels in canine atrial cells. Differences in kinetics, selectivity, and pharmacology

  1985cited by this paper
• Two distinct populations of calcium channels in a clonal line of pituitary cells.

  1985cited by this paper
• Alignment of microscopic particles in electric fields and its biological implications.

  1985cited by this paper

• The Ca(2+) channel inhibitor efonidipine decreases voltage-dependent K(+) channel activity in rabbit coronary arterial smooth muscle cells.

  2013cites this paper
• The T-type Ca²⁺ channel inhibitor mibefradil inhibits voltage-dependent K⁺ channels in rabbit coronary arterial smooth muscle cells.

  2012cites this paper
• The T-type Ca2+ Channel Inhibitor Mibefradil Inhibits Voltage-Dependent K+ Channels in Rabbit Coronary Arterial Smooth Muscle Cells

  2012cites this paper
• Chapter 100 – β-Blockers and Calcium Channel Blockers as Antiarrhythmic Drugs

  2004cites this paper
• Contribution of nifedipine-insensitive voltage-dependent Ca2+ channel to diameter regulation in rabbit mesenteric artery.

  2002cites this paper
• T‐channel‐like pharmacological properties of highvoltage‐activated, nifedipine‐insensitive Ca2+ currents inthe rat terminal mesenteric artery

  2002cites this paper
• How to use calcium antagonists in hypertension: putting the JNC-VI guidelines into practice. Joint National Committee for the Prevention, Detection, Evaluation and Treatment of High Blood Pressure.

  1999cites this paper
• How to Use Calcium Antagonists in Hypertension

  1999cites this paper
• William Howard Frishman, MD: a conversation with the editor. Interview by William Clifford Roberts.

  1998cites this paper
• Chapter 32 - To Market, To Market - 1997

  1998cites this paper
• Additional antianginal and anti‐ischemic efficacy of mibefradil in patients concomitantly treated with long‐acting nitrates for chronic stable angina pectoris

  1998cites this paper